Welcome to our dedicated page for Adicet Bio news (Ticker: ACET), a resource for investors and traders seeking the latest updates and insights on Adicet Bio stock.
Adicet Bio Inc (ACET) is a clinical-stage biotechnology company pioneering allogeneic gamma delta T cell therapies for cancer treatment. This page serves as the definitive source for verified corporate developments, research milestones, and strategic updates.
Investors and industry observers will find timely updates on clinical trial progress, regulatory milestones, and partnership announcements. Our curated collection includes press releases covering therapy pipeline advancements, financial disclosures, and scientific collaborations, with particular focus on the company's CAR/TCR engineering platform and TCR-like antibody research.
Key content categories include updates on lead candidate ADI-001 for B-cell malignancies, preclinical developments for solid tumor targets like CD70, and strategic initiatives such as the Regeneron Pharmaceuticals collaboration. All materials are vetted for accuracy and relevance to investment analysis.
Bookmark this page for streamlined access to essential updates about Adicet Bio's innovative approach to universal cell therapies. Check regularly for new developments in their mission to advance off-the-shelf immunotherapies for oncology applications.
Adicet Bio (Nasdaq: ACET) granted inducement awards on October 31, 2025 to five employees hired in October 2025. In aggregate, the company issued non-qualified stock options to purchase 97,200 shares at an exercise price of $0.75 per share (Nasdaq closing price on October 31, 2025).
The options vest 25% after one year and the remaining 75% monthly over 36 months, with full vesting on the fourth anniversary of each hire subject to continued employment. Awards were granted outside the company’s stockholder-approved plans under Adicet’s 2022 Inducement Plan and were authorized by the compensation committee as an inducement under Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston on November 11, 2025 at 3:00 p.m. ET.
The event runs November 10–12, 2025. A live audio webcast will be available on the company's Investors website and an archived replay will be accessible for 30 days after the presentation.
Adicet Bio (Nasdaq: ACET) announced the first patient has been dosed in its Phase 1 trial of ADI-001 for treatment-refractory rheumatoid arthritis (RA) on October 16, 2025. The program is enrolling across seven autoimmune conditions and will test two conditioning regimens: cyclophosphamide alone and cyclophosphamide plus fludarabine. Preliminary clinical data are expected in 2H/2026. The company cited prior promising safety and efficacy findings for ADI-001 in lupus nephritis and systemic lupus erythematosus as encouragement for broader autoimmune potential.
Adicet Bio (Nasdaq: ACET) announced an underwritten registered direct offering expected to raise approximately $80.0 million in gross proceeds. The company is selling 70,001,000 shares of common stock at $1.00 per share and, to certain investors, pre-funded warrants exercisable for 10,000,000 shares priced at $0.9999 each (exercise price $0.0001 per warrant).
The offering is expected to close on or about October 8, 2025, subject to customary conditions, and is being underwritten by Jefferies, Guggenheim Securities, Truist Securities, Wedbush PacGrow, and H.C. Wainwright. Securities are offered under an S-3 shelf registration declared effective March 14, 2025.
Adicet Bio (Nasdaq: ACET) reported positive preliminary Phase 1 data for ADI-001 in lupus nephritis (LN) and systemic lupus erythematosus (SLE) as of the August 31, 2025 data cut-off. All seven evaluable patients (five LN, two SLE) showed rapid, sustained SLEDAI-2K and PGA score reductions and immune reset signals after a single dose. All five LN patients achieved renal responses (three complete responses with DORIS remissions, two partial responses), with responses ongoing. ADI-001 was generally well tolerated (no SAEs, no ICANS, two Grade 1 CRS, one Grade 1 infection). More than 25 sites are open; Adicet plans an FDA meeting in 1Q/2026 and anticipates a pivotal study start in 2Q/2026.
Adicet Bio (Nasdaq: ACET), a clinical-stage biotech company focused on allogeneic gamma delta T cell therapies, has granted an inducement award to a new employee. The award consists of non-qualified stock options to purchase 9,800 shares at an exercise price of $0.81 per share.
The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments. The award was granted under Adicet's 2022 Inducement Plan and approved by the compensation committee as a material inducement for employment, in accordance with Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference. The company's President and CEO, Chen Schor, will deliver a presentation on September 8, 2025, at 4:30 p.m. ET in New York.
Investors can access the live audio webcast through Adicet Bio's website, with a replay available for 30 days after the presentation.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on allogeneic gamma delta T cell therapies, has granted inducement awards to two new employees in August 2025. The awards consist of non-qualified stock options to purchase 84,000 shares of common stock at $0.72 per share.
The stock options will vest over four years, with 25% vesting after one year and the remaining 75% vesting in 36 monthly installments. These awards were granted under Adicet's 2022 Inducement Plan as approved by the compensation committee, following Nasdaq Listing Rule 5635(c)(4).
Adicet Bio (Nasdaq: ACET) reported Q2 2025 financial results and provided significant updates on its clinical programs. The company is actively enrolling patients in its Phase 1 clinical trial of ADI-001 for multiple autoimmune diseases, including lupus nephritis, systemic lupus erythematosus, and systemic sclerosis, with preliminary data expected in 2H/2025.
The company is prioritizing the development of ADI-212, a next-generation gene-edited therapy for prostate cancer, with regulatory filing expected in Q1 2026. As part of strategic pipeline prioritization, Adicet discontinued ADI-270 development and reduced its workforce by 30%. Financial results showed a net loss of $31.2 million for Q2 2025, with cash position of $125.0 million expected to fund operations into Q4 2026.
Adicet Bio (Nasdaq: ACET), a clinical stage biotechnology company focused on developing allogeneic gamma delta T cell therapies, announced its participation in the 45th Annual Canaccord Genuity Growth Conference. Chen Schor, President and CEO, will engage in a fireside chat on August 12, 2025, at 1:30 p.m. ET in Boston.
The presentation will be accessible via live audio webcast through Adicet Bio's investor relations website, with a replay available for 30 days after the event.
FAQ
What is the current stock price of Adicet Bio (ACET)?
What is the market cap of Adicet Bio (ACET)?
